Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim

Last Updated: December 6, 2021

DrugPatentWatch Database Preview

Patent: 8,097,238

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 8,097,238
Title:Cell targeting conjugates
Abstract: The present invention relates to cell targeting conjugates and in particular, but not exclusively, to methods of their use in selectively eliminating and in selectively imaging target cells. The invention also relates to processes for production of the conjugates and to intermediate compounds that may be used in production of a specific class of cell targeting conjugates. In one embodiment there is provided a cell targeting conjugate comprising the following components that are covalently conjugated via a linker that is degradable within the target cells: i) a DNA minor groove binding ligand incorporating an effective Auger electron-emitting and/or gamma-emitting and/or positron-emitting atom or photoactive moiety; ii) a target cell specific protein or peptide that is capable of internalization by target cells.
Inventor(s): Martin; Roger Francis (Ivanhoe, AU), White; Jonathan Michael (Wheelers Hill, AU), Lobachevsky; Pavel Nikolaevich (Bulleen, AU), Karagiannis; Thomas Chris (Thornbury, AU)
Assignee: Peter MacCallum Cancer Institute (East Melbourne, AU)
Application Number:10/590,784
Patent Claims:see list of patent claims

Details for Patent 8,097,238

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 1998-09-25 ⤷  Free Forever Trial 2024-02-27
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 2017-02-10 ⤷  Free Forever Trial 2024-02-27
Genzyme Corporation CAMPATH alemtuzumab Injection 103948 2001-05-07 ⤷  Free Forever Trial 2024-02-27
Genzyme Corporation LEMTRADA alemtuzumab Injection 103948 2014-11-14 ⤷  Free Forever Trial 2024-02-27
Genzyme Corporation CAMPATH alemtuzumab Injection 103948 2004-10-12 ⤷  Free Forever Trial 2024-02-27
Glaxosmithkline Llc BEXXAR tositumomab and iodine i-131 tositumomab Injection 125011 2003-06-27 ⤷  Free Forever Trial 2024-02-27
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.